Previous radiation for prostate XXXX alters surgical and oncologic outcomes after @entity5 surgery.

@entity1 @entity137 @entity834 @entity263 @entity5
BACKGROUND: Previous radiation for @entity263 ( @entity263 ) contra-indicates neoadjuvant chemoradiotherapy for @entity5 ( @entity5 ) because of risk of cumulative radiation dose @entity137 . Postoperative outcomes after proctectomy have not been well studied in these @entity1 who did not receive optimal treatment. METHODS: Eighty-four consecutive male @entity1 underwent surgery for stage II-III mid or low @entity5 between 2002 and 2011. @entity1 who previously received radiation for @entity263 (n   =   8) and @entity1 who had not previously undergone radiation for @entity263 but who received neoadjuvant chemoradiotherapy for @entity5 (n   =   64) were retrospectively compared. RESULTS: Previous radiation for @entity263 was an independent factor that significantly increased intraoperative (25% vs. 1.6%, P   =   0.002) and postoperative morbidities (62.5% vs. 28.1%, P   =   0.028), @entity834 (62.5% vs. 12.5%, P   <   0.001) and definitive stoma rates (25% vs. 17.4%, P   =   0.022). It significantly altered median overall survival (32.0 vs. 130.6 months, P   =   0.05) and local recurrence-free survival rates (14.0 months vs. "median not reached," P   =   0.016). CONCLUSIONS: This is the first report of altered survival rates after proctectomy in @entity1 who had previously received radiation for @entity263 . Postoperative morbidity and definitive defunctioning stoma rates were significantly increased in these @entity1 with poor prognoses. Therapeutic strategies should thus be individualized. Large, multicenter cohort studies are needed. J. Surg. Oncol.    2015 Wiley Periodicals, Inc.
